Novel therapeutic options and drug targets in MS

Effects of dimethyl fumarate on neuroprotection and immunomodulation

(2012) Philipp Albrecht et al.   Journal of Neuroinflammation

T cells become licensed in the lung to enter the central nervous system

(2012) Francesca Odoardi et al.   NATURE

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

(2012) Adam P. Gregory et al.   NATURE

Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis

(2012) Rajneesh Srivastava et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity

(2012) Ulf Schulze-Topphoff et al.   PLoS One

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Insight into the mechanism of laquinimod action

(2011) W. Brück et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES